Michael Rauh PhD, MD, FRCPC
Member, Division of Cancer Biology & Genetics
Our focus is on myelodysplastic syndromes (MDS) and myeloid innate immunity.
We strive to provide novel and more objective genomic and proteomic tests, in order to detect myeloid cancer earlier and better inform treatment. Moreover, by understanding how cancers manipulate the innate immune environment, we hope to discover novel biomarkers and treatment targets. Applying this knowledge, our goal is to provide more personalized diagnosis and care.